Cancer Chemotherapy and Pharmacology

, Volume 62, Issue 5, pp 925–927

Oxaliplatin-induced immune mediated thrombocytopenia

  • Muhammad S. Beg
  • Rami S. Komrokji
  • Kashif Ahmed
  • Malek M. Safa
Short Communication

DOI: 10.1007/s00280-007-0675-5

Cite this article as:
Beg, M.S., Komrokji, R.S., Ahmed, K. et al. Cancer Chemother Pharmacol (2008) 62: 925. doi:10.1007/s00280-007-0675-5

Abstract

Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.

Keywords

OxaliplatinImmuneThrombocytopenia

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Muhammad S. Beg
    • 1
  • Rami S. Komrokji
    • 1
  • Kashif Ahmed
    • 1
  • Malek M. Safa
    • 1
    • 2
  1. 1.Department of MedicineUniversity of CincinnatiCincinnatiUSA
  2. 2.Hematology/Oncology Fellowship ProgramUniversity of Cincinnati/Barrett Cancer CenterCincinnatiUSA